Clinical Trial · NCT06696326

A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer

Overview

The main objective of this research is to develop and evaluate new PET imaging agents with high sensitivity and specificity for prostate cancer and other aggressive tumors. Specifically, the research focuses on improving upon existing prostate cancer imaging methods, such as PSA tests and PSMA PET/CT, which have limitations in sensitivity, specificity, and the ability to provide comprehensive tumor information,and aims to create a novel PET probe targeting Trop2, an antigen highly expressed in multiple cancer types, to enable in vivo, whole-tumor assessment. This would support early diagnosis, more precise staging, and effective monitoring of cancer therapy.

Phase

N/A

Contacts

Chen Haojun, MD, PhD

leochen0821@foxmail.com

+8618659285282

ClinicalTrials.gov

NCT06696326

Drug / Compound

68Ga-MY6349

Isotope(s):
Target(s):
  • Trop-2

68Ga-PSMA-11

Isotope(s):
Target(s):
  • PSMA